CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted EBT Margin of 8373.94% for Q1 2026, up 55.48% sequentially from 18810.88% in Q4 2025, and up 721994.0% YoY from N/an in Q1 2025.
CRISPR Therapeutics AG (CRSP) EBT Margin (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported EBT Margin for 11 years, with the latest figure at 8373.94% in Q1 2026.
- Quarterly EBT Margin rose 721994.0% year-over-year to 8373.94% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14567.32% (down 1462627.0% YoY) and the FY2025 annual result came in at 17392.93%, down 1750343.0% from the prior year.
- EBT Margin climbed to 8373.94% in Q1 2026 per CRSP's latest filing, from 18810.88% in the prior quarter.
- Over five years, EBT Margin peaked at 1029.07% in Q4 2024 and troughed at 2000850.0% in Q4 2022.
- A 5-year average of 153619.05% and a median of 17137.84% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2023: EBT Margin sank 199973750 bps in 2022, then surged 200089452 bps in 2023.
- Over 5 years, EBT Margin stood at 2000850.0% in 2022, then jumped by 100 bps to 44.52% in 2023, then jumped by 2211 bps to 1029.07% in 2024, then slumped by 1928 bps to 18810.88% in 2025, then surged by 55 bps to 8373.94% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 8373.94%, 18810.88%, and 11903.49% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -885.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -885.91% |
| Mar 31, 2026 | -8,373.94% |
| Dec 31, 2025 | -18,810.88% |
| Sep 30, 2025 | -11,903.49% |
| Jun 30, 2025 | -23,235.09% |
| Mar 31, 2025 | -15,593.87% |
| Dec 31, 2024 | 1,029.07% |
| Sep 30, 2024 | -14,130.56% |
| Jun 30, 2024 | -24,201.35% |
| Mar 31, 2024 | -22,989.48% |
| Dec 31, 2023 | 44.52% |
| Jun 30, 2023 | -109.74% |
| Mar 31, 2023 | -51.75% |
| Dec 31, 2022 | -2,000,850.00% |
| Sep 30, 2022 | -186,302.13% |
| Jun 30, 2022 | -113,744.30% |
| Mar 31, 2022 | -18,681.81% |
| Dec 31, 2021 | -1,112.50% |
| Sep 30, 2021 | -15,503.40% |
| Jun 30, 2021 | 84.75% |